StockData

GH Research vs Rein Therapeutics

GHRS and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GHRS and RNTX compare

Rein Therapeutics scores higher on the StockData Score (6 against 1 for GH Research), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGHRSRNTX
Size and price
Market cap–$30.7M
Share price$18.27$0.356
Change, 1 year30.5%−71.5%
Change, 5 years−17.7%−97.3%
Beta (5Y)1.802.30
Employees7310
StockData Score
Total score16 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/B–0.6×
Profitability
Return on equity–−96.4%
Return on invested capital–−145%
Financial health
Debt / equity–0.00
Interest coverage−257.1×–
Current ratio28.70 (better)4.27
Altman Z-score–−8.96
Piotroski F-score3 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield–−179%
Shareholder yield–−179%
Ownership
Held by institutions83.0%47.3%
Held by insiders45.6%9.6%
Insider net buying, 12 months–$74.7K
Short interest, % of float6.2%0.91%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.